<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01421498</url>
  </required_header>
  <id_info>
    <org_study_id>1118-KCS-200</org_study_id>
    <nct_id>NCT01421498</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE)</brief_title>
  <acronym>OPUS-1</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double- Masked and Placebo-Controlled Study Evaluating the Efficacy of a 5.0% Concentration of SAR 1118 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (OPUS-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy of SAR 1118 Ophthalmic Solution (5.0%)
      compared to placebo in the treatment of Dry Eye. The safety and tolerability of SAR 1118
      Ophthalmic Solution (5.0%) compared to placebo in subjects with dry eye when administered BID
      for 12 weeks will also be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Sign: Change From Baseline in Inferior Corneal Fluorescein Staining to Day 84</measure>
    <time_frame>Baseline (Day 0) to Day 84</time_frame>
    <description>Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. The staining was graded with the Ophthalmic Research Associates, Inc. (ORA) scale. The corneal surface is divided into three regions: superior, central and inferior. The scores for each of these 3 regions ranged from 0 to 4 (0=no staining/none; 1=occasional/trace; 2=countable/mild; 3=uncountable, but not confluent/moderate; 4=confluent/severe) with 0.5 point increments, and lower score indicates a better outcome. Inferior corneal fluorescein staining scores from the study eye only were reported. Study eye is the 'worse eye', defined as the eye with worse (higher) score at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Symptom: Change From Baseline in Visual-Related Subscale of the Symptom Functional Scale Score to Day 84</measure>
    <time_frame>Baseline (Day 0) to Day 84</time_frame>
    <description>The symptom functional scale is a validated instrument for ocular surface diseases, measuring the ocular symptoms, vision-related function, and environmental triggers. The 12 items of the symptom functional scale questionnaire were graded on a scale of 0 (none of the time) to 4 (all of the time). The index consisted of 3 sub scales: symptoms (sensitivity to light, gritty sensation, pain, blurred vision, and poor vision [Items 1-5]), visual-related sub scale of the symptom functional scale (ability to read, drive at night, use a computer, watch television [Items 6-9]), and environmental triggers (windy conditions, low humidity, air conditioning [Items 10-12]). The symptom functional scale was scored on a scale of 0 to 100, with higher scores representing greater disability. Negative change from baseline indicates improvement.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">588</enrollment>
  <condition>Dry Eye</condition>
  <condition>Keratoconjunctivitis Sicca</condition>
  <arm_group>
    <arm_group_label>5.0% Lifitegrast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lifitegrast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lifitegrast</intervention_name>
    <description>Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: 12 weeks</description>
    <arm_group_label>5.0% Lifitegrast</arm_group_label>
    <other_name>SAR 1118</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dosage Form: Ophthalmic Solution Frequency: BID Duration: 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to read, sign, and date the informed consent and HIPAA documents

          -  Willing and able to comply with all study procedures

          -  Be at least 18 years of age

          -  Patient-reported history of dry eye in both eyes

          -  Demonstrate a positive response when exposed to the Controlled Adverse Environment
             model

          -  A negative urine pregnancy test if female of childbearing potential and must use
             adequate birth control throughout the study period

        Exclusion Criteria:

          -  Any ocular condition that, in the opinion of the Investigator, could affect study
             parameters including, but not limited to, active ocular infection, ocular
             inflammation, glaucoma, and/or diabetic retinopathy

          -  Unwilling to avoid wearing contact lenses for 7 days prior to and for duration of the
             study period

          -  Any blood donation or significant loss of blood within 56 days of Visit 1

          -  Any history of immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of
             acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant.

          -  Use of any topical ophthalmic preparations (including artificial tear substitutes) 72
             hrs prior to Visit 1 and during the study

          -  Any significant chronic illness that could interfere with study parameters

          -  History of laserâ€‘assisted in situ keratomileusis (LASIK) or similar type of corneal
             refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical
             procedure within 12 months prior to Visit 1; or any scheduled ocular surgical
             procedure during the study period.

          -  Known history of alcohol and/or drug abuse

          -  Subjects with Dry eye secondary to scarring or destruction of conjunctival goblet
             cells (as with Vitamin A deficiency)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Semba, MD</last_name>
    <role>Study Director</role>
    <affiliation>SARcode Bioscience, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OPUS-1 Investigational Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OPUS-1 Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OPUS-1 Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Maine</state>
        <zip>04330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OPUS-1 Investigational Site</name>
      <address>
        <city>Lewiston</city>
        <state>Maine</state>
        <zip>04243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OPUS-1 Investigational Site</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OPUS-1 Investigational Site</name>
      <address>
        <city>Lancaster</city>
        <state>Massachusetts</state>
        <zip>01523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OPUS-1 Investigational Site</name>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <zip>02169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OPUS-1 Investigational Site</name>
      <address>
        <city>Wakefield</city>
        <state>Massachusetts</state>
        <zip>01880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OPUS-1 Investigational Site</name>
      <address>
        <city>Winchester</city>
        <state>Massachusetts</state>
        <zip>01890</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OPUS-1 Investigational Site</name>
      <address>
        <city>Derry</city>
        <state>New Hampshire</state>
        <zip>03038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OPUS-1 Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>New Hampshire</state>
        <zip>03101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OPUS-1 Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OPUS-1 Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2011</study_first_submitted>
  <study_first_submitted_qc>August 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2011</study_first_posted>
  <results_first_submitted>November 9, 2015</results_first_submitted>
  <results_first_submitted_qc>January 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 24, 2017</results_first_posted>
  <disposition_first_submitted>July 2, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>July 2, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 9, 2013</disposition_first_posted>
  <last_update_submitted>January 5, 2017</last_update_submitted>
  <last_update_submitted_qc>January 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Eye</keyword>
  <keyword>ophthalmic delivery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Lifitegrast</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study was conducted in a Controlled Adverse Environment (CAE).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lifitegrast 5.0%</title>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="293"/>
                <participants group_id="P2" count="295"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="281"/>
                <participants group_id="P2" count="284"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all randomized participants who received at least 1 dose of investigational product.</population>
      <group_list>
        <group group_id="B1">
          <title>Lifitegrast 5.0%</title>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="293"/>
            <count group_id="B2" value="295"/>
            <count group_id="B3" value="588"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.2" spread="12.21"/>
                    <measurement group_id="B2" value="61.1" spread="11.77"/>
                    <measurement group_id="B3" value="60.6" spread="11.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="217"/>
                    <measurement group_id="B3" value="446"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ocular Sign: Change From Baseline in Inferior Corneal Fluorescein Staining to Day 84</title>
        <description>Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. The staining was graded with the Ophthalmic Research Associates, Inc. (ORA) scale. The corneal surface is divided into three regions: superior, central and inferior. The scores for each of these 3 regions ranged from 0 to 4 (0=no staining/none; 1=occasional/trace; 2=countable/mild; 3=uncountable, but not confluent/moderate; 4=confluent/severe) with 0.5 point increments, and lower score indicates a better outcome. Inferior corneal fluorescein staining scores from the study eye only were reported. Study eye is the â€˜worse eyeâ€™, defined as the eye with worse (higher) score at baseline.</description>
        <time_frame>Baseline (Day 0) to Day 84</time_frame>
        <population>Intent-to-Treat (ITT) population with Last Observation Carried Forward (LOCF) included all randomized participants who received at least 1 dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Lifitegrast 5.0%</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Ocular Sign: Change From Baseline in Inferior Corneal Fluorescein Staining to Day 84</title>
          <description>Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. The staining was graded with the Ophthalmic Research Associates, Inc. (ORA) scale. The corneal surface is divided into three regions: superior, central and inferior. The scores for each of these 3 regions ranged from 0 to 4 (0=no staining/none; 1=occasional/trace; 2=countable/mild; 3=uncountable, but not confluent/moderate; 4=confluent/severe) with 0.5 point increments, and lower score indicates a better outcome. Inferior corneal fluorescein staining scores from the study eye only were reported. Study eye is the â€˜worse eyeâ€™, defined as the eye with worse (higher) score at baseline.</description>
          <population>Intent-to-Treat (ITT) population with Last Observation Carried Forward (LOCF) included all randomized participants who received at least 1 dose of investigational product.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.868"/>
                    <measurement group_id="O2" value="0.17" spread="0.819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Treatment difference</param_type>
            <param_value>0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Symptom: Change From Baseline in Visual-Related Subscale of the Symptom Functional Scale Score to Day 84</title>
        <description>The symptom functional scale is a validated instrument for ocular surface diseases, measuring the ocular symptoms, vision-related function, and environmental triggers. The 12 items of the symptom functional scale questionnaire were graded on a scale of 0 (none of the time) to 4 (all of the time). The index consisted of 3 sub scales: symptoms (sensitivity to light, gritty sensation, pain, blurred vision, and poor vision [Items 1-5]), visual-related sub scale of the symptom functional scale (ability to read, drive at night, use a computer, watch television [Items 6â€“9]), and environmental triggers (windy conditions, low humidity, air conditioning [Items 10â€“12]). The symptom functional scale was scored on a scale of 0 to 100, with higher scores representing greater disability. Negative change from baseline indicates improvement.</description>
        <time_frame>Baseline (Day 0) to Day 84</time_frame>
        <population>ITT population with LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Lifitegrast 5.0%</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Ocular Symptom: Change From Baseline in Visual-Related Subscale of the Symptom Functional Scale Score to Day 84</title>
          <description>The symptom functional scale is a validated instrument for ocular surface diseases, measuring the ocular symptoms, vision-related function, and environmental triggers. The 12 items of the symptom functional scale questionnaire were graded on a scale of 0 (none of the time) to 4 (all of the time). The index consisted of 3 sub scales: symptoms (sensitivity to light, gritty sensation, pain, blurred vision, and poor vision [Items 1-5]), visual-related sub scale of the symptom functional scale (ability to read, drive at night, use a computer, watch television [Items 6â€“9]), and environmental triggers (windy conditions, low humidity, air conditioning [Items 10â€“12]). The symptom functional scale was scored on a scale of 0 to 100, with higher scores representing greater disability. Negative change from baseline indicates improvement.</description>
          <population>ITT population with LOCF.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.829"/>
                    <measurement group_id="O2" value="-0.12" spread="0.762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7860</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Treatment difference</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lifitegrast 5.0%</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-Cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="293"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation site irritation</sub_title>
                <counts group_id="E1" events="70" subjects_affected="69" subjects_at_risk="293"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Instillation site pain</sub_title>
                <counts group_id="E1" events="63" subjects_affected="63" subjects_at_risk="293"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Instillation site pruritus</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="293"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="295"/>
              </event>
              <event>
                <sub_title>Instillation site reaction</sub_title>
                <counts group_id="E1" events="52" subjects_affected="50" subjects_at_risk="293"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="39" subjects_at_risk="293"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="295"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicentre publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicentre Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire</organization>
      <phone>1 866-842-5335</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

